ADGRG2 |
Tethered peptide agonist |
TSFGILLDLSRTSLP |
Agonist |
|
Demberg et al., 2015 |
AGTR2
|
Angiotensin II
(ANG II)
|
Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8
|
Agonist
|
Clinic
|
Guimond et al., 2014; Hallberg et al., 2018
|
|
Saralasin |
[Sar1,Val5,Ala8]Ang
II |
Agonist |
Clinic |
Guimond et al., 2014; Hallberg et al.,
2018 |
|
Sarile |
[Sar1,Ile8]Ang II |
Agonist |
Clinic |
Guimond et al., 2014;
Hallberg et al., 2018 |
|
MP-157 |
No structural formula is disclosed |
Agonist |
Phase I |
Hallberg et al., 2018 |
|
C21/M24 |
|
Agonist |
Phase II |
Hallberg et al.,
2018 |
|
C38/M132 |
|
Antagonist |
|
Hallberg et al.,
2018 |
LGR4 |
R-spondins |
R-spondin1-4(RSPO1-4) |
Agonist |
|
Carmon et al., 2011; de Lau et al.,
2011; Glinka et al., 2011 |
|
Norrin |
MRKHVLAASFSMLSLLVIMGDTDSKTDSSFIMDSDPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYILSCHCEECNS |
Agonist |
|
Deng et al., 2013 |
|
TNFSF11(RANKL) |
Tumor necrosis factor (TNF) superfamily member 11 |
Agonist |
|
Luo et al., 2016 |
GPER |
G-1 |
|
Agonist |
|
Bologa et al., 2006 |
|
G15 |
|
Antagonist |
|
Dennis et al., 2009; Dennis et al., 2011 |
|
G36 |
|
Antagonist |
|
Dennis et al., 2011 |
A1AR
|
Trabodenoson
(INO-8875)
|
|
partial agonist
|
Phase III
|
Jacobson et al., 2019
|
A2AAR |
Regadenoson |
|
agonist |
|
Jacobson et al., 2019 |
A3AR |
IB-MECA |
|
agonist |
Phase III |
Jacobson et al., 2019 |